Physician profile
Daniel Bensimhon
NPI 1245293505
$2,099,769.03
in general payments reported to CMS, 2019-2025
49 companies · $323K in 2025
The $323K reported for 2025 was more than what 99% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349K · 2020: $235K · 2021: $274K · 2022: $379K · 2023: $299K · 2024: $240K · 2025: $323K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $623K · Consulting Fee: $176K · Honoraria: $24K · Travel and Lodging: $24K · Food and Beverage: $11K · Education: $3,357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $623,481.50 |
| Consulting Fee | $176,055.00 |
| Honoraria | $24,372.96 |
| Travel and Lodging | $23,771.80 |
| Food and Beverage | $11,137.78 |
| Education | $3,356.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sensible Medical Innovations INC | $318,225.44 | 2019-2025 | Reds System |
| Actelion Pharmaceuticals US, INC. | $295,730.92 | 2019-2025 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $259,275.72 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $185,798.67 | 2019-2025 | Jardiance |
| Ge Healthcare | $167,900.00 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $147,141.82 | 2020-2025 | |
| Caption Health, INC. | $120,026.00 | 2022-2024 | |
| Scpharmaceuticals INC. | $105,372.76 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $93,448.26 | 2019-2025 | Lokelma, Farxiga, Wainua |
| Novartis Pharmaceuticals Corporation | $88,722.76 | 2019-2021 | |
| Irhythm Technologies, INC. | $85,734.29 | 2019-2024 | Zio Xt Patch, Zio Monitor |
| Pfizer INC. | $71,538.72 | 2019-2025 | |
| Itamar Medical INC | $43,826.66 | 2020-2025 | Watchpatone |
| E.R. Squibb & Sons, L.L.C. | $34,251.21 | 2019-2024 | Eliquis |
| Merck Sharp & Dohme LLC | $33,792.98 | 2021-2025 | Winrevair |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sensible Medical Innovations LTD | $13,826.95 | 2022-2023 | Reds System |
| Bridgebio Pharma, INC. | $6,174.86 | 2025 | Attruby |
| Baxter Healthcare | $5,544.28 | 2019-2020 | |
| Boston Scientific Corporation | $4,603.45 | 2019-2023 | |
| Novo Nordisk INC | $4,520.41 | 2022-2024 | Rybelsus, Ozempic |
| Medicure Pharma INC. | $3,000.00 | 2019 | |
| Eli Lilly and Company | $3,000.00 | 2020 | |
| Boehringer Ingelheim International Gmbh | $2,125.00 | 2020 | |
| Abbott Laboratories | $1,262.85 | 2019-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Biotronik INC. | $926.14 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $873.94 | 2019-2024 | Xarelto |
| Amgen INC. | $751.51 | 2019-2025 | Repatha, Repatha |
| Abiomed | $510.87 | 2019-2024 | Impella |
| Zoll Medical Corporation | $306.67 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $295.08 | 2019-2024 | Lifevest |
| Inari Medical, INC. | $233.52 | 2021 | |
| United Therapeutics Corporation | $160.59 | 2020-2022 | |
| Cvrx, INC. | $150.53 | 2022-2024 | Barostim Neo System |
| Medtronic Vascular, INC. | $144.79 | 2019 | |
| Alnylam Pharmaceuticals INC. | $123.08 | 2019 | |
| Arbor Pharmaceuticals, INC. | $93.56 | 2019-2020 | |
| Kestra Medical Technology Services, INC. | $73.56 | 2025 | Assure Wcd |
| Otsuka America Pharmaceutical, INC. | $43.28 | 2019 | |
| Portola Pharmaceuticals, LLC | $41.88 | 2019-2020 | |
| Medtronic, INC. | $36.40 | 2021-2025 | Biomedicus |
| Vifor Pharma, INC. | $34.23 | 2019 | |
| Haemonetics Corporation | $30.78 | 2024 | Teg6s Hemostasis System |
| Stryker Corporation | $28.88 | 2025 | Flowtriever |
| Gilead Sciences, INC. | $27.28 | 2019 | |
| Daiichi Sankyo INC. | $25.38 | 2020 | |
| Impulse Dynamics (USA) INC. | $13.07 | 2023 | Optimizer |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$293,354.82 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Bensimhon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.